In order to protect patients and users of certain products, it is necessary to design study to assess the interaction between the released or migrated components into the pharmaceutical product and the possible health risk to the user.

Read More

Nitrosamines represent one of the first risks of contamination in pharmaceutical products and basic active ingredients: listed as carcinogenic mutagens, nitrosamines can be tolerated when complying to...

Read More

An analysis conducted on the risk assessment allows companies and administrations to meet the increasingly high standards of safety in the FCM context. Indeed, food contact materials are subject ...

Read More